In the crowded oral GLP-1 field, gastrointestinal tolerability — not weight loss — decides the winners.
As a wave of oral small-molecule programs from Viking, Roche, AstraZeneca, Kailera, and Structure converges on competitive double-digit weight loss, commercial survival turns on GI side-effect rates, discontinuation risk, and dosing convenience.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Competitive 9.8% weight loss is overshadowed by GI rates analysts say must fall to the mid-30s to stay commercially viable — tolerability, not efficacy, is the gating variable.
AstraZeneca earns its Phase 3 advance on infrequent discontinuations and no-fasting convenience even with mid-pack efficacy, as the oral market crowds into a tolerability contest.